pre-IPO PHARMA

COMPANY OVERVIEW

eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis has the capability to solve the global organ crisis by providing an alternative to allotransplantation.


LOCATION

  • Cambridge, MA, USA
  • New York, NY, USA

  • THERAPEUTIC AREAS


    WEBSITE

    https://www.egenesisbio.com


    CAREER WEBSITE

    https://www.egenesisbio.com/careers/


    SOCIAL MEDIA


    INVESTORS

    alta-partners arch-venture-partners biomatics-capital fresenius-medical-care-ventures khosla-ventures leaps-by-bayer wellington-partners


    PRESS RELEASES


    Jun 13, 2023

    eGenesis Announces Publication in Nature Communications Characterizing Renal Physiology and Endocrine Function in Non-Human Primates Post Xenograft Transplant


    Jun 5, 2023

    eGenesis Presents New Data on Long-Term Survival in Preclinical Kidney Xenotransplantation at American Transplant Congress 2023


    Jan 24, 2023

    eGenesis Announces Knut Niss as Chief Technology Officer


    Jan 9, 2023

    eGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies


    Apr 19, 2022

    eGenesis Promotes Michael Curtis, Ph.D., to Chief Executive Officer


    For More Press Releases


    Google Analytics Alternative